In addition, the expression levels of glycolytic enzymes (GCK, PFK, and PK), p-GSK3β/GSK3β, and lipolytic enzymes (PPARα) were upregulated, whereas hepatic gluconeogenic enzymes (G-6-P and PEPCK) and fatty-acid synthesis enzymes (SREBP-1c) were decreased after HucMDE treatment in T2DM rats and in PA-induced L-O2 cells, indicating that HucMDEs alleviated glucose and lipid metabolism dysfunction both in vivo and in vivo. This evidence concerns the gene GSK3B and type 2 diabetes mellitus.